查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1930024

亨汀頓氏舞蹈症治療市場規模、佔有率、成長及全球產業分析：依藥物、通路和地區劃分的洞察與預測（2025-2034）

Huntington's Disease Treatment Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2025-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 133 Pages | 商品交期: 請詢問到貨日

價格

亨汀頓氏舞蹈症治療市場成長驅動因素

到2025年，全球亨汀頓氏舞蹈症治療市場規模達到13.9億美元，這反映出人們對這種罕見進行性神經退化性疾病症狀管理療法的需求日益成長。預計到2026年，該市場規模將達到15.3億美元，並在2034年成長至43.3億美元，預測期內年複合成長率（CAGR）為13.9%。 市場成長得益於已開發地區疾病盛行率的上升、公眾意識的增強以及針對新型治療方法的研究活動的增加。

亨汀頓氏舞蹈症（HD）是一種遺傳性疾病，患者腦內的神經細胞會逐漸退化，導致運動功能障礙、認知能力下降和精神障礙。雖然目前尚無治癒方法，但已核准的藥物療法可以有效控制舞蹈症及相關症狀。目前，tetrabenazine、Deutetrabenazine和valbenazine是全球唯一核准用於治療亨汀頓氏舞蹈症患者舞蹈症的藥物。

市場成長驅動因素

市場成長的主要驅動因素是亨廷頓病患病率的上升，尤其是在北美和歐洲。預計到2023年，北美地區的發病率將達到每 10萬人 8.87 例，歐洲將達到每 10萬人 6.37 例，這將導致對治療干預措施的持續需求。 中國和印度等新興經濟體診斷率的上升也進一步推動了治療方案的普及。

另一個關鍵驅動因素是政府機構和研究組織積極參與提高公眾意識和資助臨床開發計畫。公私合作和撥款資助加速目的是延緩疾病進展的臨床試驗。診斷意識的提高促使治療更早啟動，並擴大了目標患者群體。

市場限制因子

儘管成長前景良好，但市場面臨著與長期用藥相關的副作用挑戰。已獲批准的治療藥物，例如deutetrabenazine和valbenazine，都存在抑鬱、自殺意念、鎮靜和心律不整等副作用的警告。這些安全問題可能會限制患者的用藥依從性和處方模式，尤其是在弱勢患者群體中。

此外，罕見疾病治療藥物嚴格的監管要求和漫長的審批流程可能會阻礙候選藥物的快速商業化，並減緩新型療法的市場滲透。

新興市場趨勢

亨汀頓氏舞蹈症治療市場最顯著的趨勢之一是先進基因和分子療法的湧現。這些療法包括反義寡核苷酸（ASO）療法、RNA干擾（RNAi）、CRISPR-Cas9基因編輯、鋅指蛋白（ZFP）療法以及基於TALEN的療法。這些新一代療法直接針對突變型亨汀頓氏舞蹈症（HTT）基因，目的是解決疾病的根本原因，而不僅僅是抑制症狀。

不斷增加的臨床研究投入和早期試驗的良好資料引起了投資者和機構投資者的極大興趣，表明治療策略正轉向疾病修飾療法。

市場區隔分析

依藥物類型

依藥物類型劃分，tetrabenazine將在2025年佔據市場主導地位，市場佔有率將達到64.21%。其主導地位歸功於它是首個獲得FDA批准用於治療亨廷頓氏症（HD）舞蹈症的藥物，以及價格實惠的仿製藥的供應。Deutetrabenazine因其更高的安全性以及每日一次的給藥方式，將佔據更大的市場佔有率。valbenazine在近期獲得監管部門批准用於治療HD相關舞蹈症後，也備受關注。 "其他" 細分市場預計將快速成長，這得益於不斷擴大的臨床研發管線和尚未滿足的醫療需求。

依通路劃分

依通路劃分，院內藥房佔據最大佔有率，預計到2026年將佔市場佔有率的47.57%，這主要得益於醫保覆蓋、專家監督和住院治療的需求。零售藥局在處方續約方面仍將發揮關鍵作用，而線上藥局預計將實現最快成長，這得益於數位化醫療的普及和送貨上門的便利性。

區域洞察

北美地區憑藉著較高的疾病認知度、完善的醫保體系和蓬勃發展的臨床研究生態系統，預計將引領全球市場，2025年市場規模將達到11.6億美元，2026年將達到12.7億美元。光是美國一地預計在2025年就將佔據12.2億美元的市場。

歐洲佔據了相當大的市場佔有率，這主要得益於新型療法的商業化努力和監管申報數量的增加。亞太地區崛起成為第二大市場，預計到2026年將達到1000萬美元，這主要得益於戰略聯盟和已獲批准藥物可及性的提高。包括拉丁美洲和中東、非洲在內的其他地區，由於患病率較低和認知度有限，成長速度較慢，但展現出長期成長潛力。

這份全球亨汀頓氏舞蹈症治療市場報告對2025年至2034年期間的產業進行了全面分析，其中2025年為基準年，2026年為估計年，2034年為預測年。報告評估了市場規模和價值趨勢、成長前景以及影響亨汀頓氏舞蹈症治療發展的結構性因素。

本研究依藥物和通路進行了詳細的細分，揭示了已獲批准的治療藥物（例如tetrabenazine、Deutetrabenazine和valbenazine）在醫院藥房、零售藥房和線上平台上的使用模式。區域分析涵蓋北美、歐洲、亞太地區和世界其他地區，深入分析了各地區的疾病盛行率、治療可近性、償付環境和研究強度。

此外，本報告還探討了市場驅動因素、限制因素、新興趨勢和在研藥物的進展。 這包括基因和分子療法的進展，例如反義寡核苷酸、RNA療法和基因編輯方法。競爭格局部分評估了主要製藥和生物技術公司的策略，重點是監管審批狀態、臨床試驗進展、合作夥伴關係和新製劑上市。本報告還涵蓋了COVID-19對診斷率、治療可及性和商業表現的影響。

市場成長主要得益於已核准的舞蹈病治療藥物的廣泛應用以及對下一代疾病修飾療法的投資不斷增加。儘管副作用和嚴格的監管要求等挑戰仍然存在，但進行中的臨床試驗和政府主導的研究計劃增強了市場的長期前景。

北美市場領先。這得歸功於較高的認知度、健全的償付體系和蓬勃發展的臨床研究生態系統。歐洲和亞太地區緊隨其後，不斷擴大的治療可及性和戰略合作夥伴關係推動市場成長。總體而言，在科學技術進步、患者群體不斷成長以及持續努力滿足未被滿足的需求的推動下，亨汀頓氏舞蹈症治療市場有望實現長期強勁成長。

目錄

第1章 引言

第2章 執行摘要

第3章 市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機會
  • 市場趨勢

第4章 主要考察

  • 主要國家和地區亨廷頓病患病率（2025年）
  • 主要產業趨勢（併購、新產品發表等）
  • 主要公司產品線分析
  • 各地區亨汀頓氏舞蹈症治療的經濟負擔
  • 主要國家的監管和償付情況區域
  • COVID-19 對全球亨汀頓氏舞蹈症治療市場的影響

第5章 全球亨汀頓氏舞蹈症治療市場分析、洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依藥物類型劃分
    • tetrabenazine
    • Deutetrabenazine
    • valbenazine
    • 其他
  • 市場分析、洞察與預測：依通路劃分
    • 醫院藥房
    • 藥局和零售藥房
    • 線上藥房
  • 市場分析、洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 其他地區全球

第6章 北美亨汀頓氏舞蹈症治療市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第7章 歐洲亨汀頓氏舞蹈症治療市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區

第8章 亞太地區亨汀頓氏舞蹈症治療市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 亞太其他地區

第9章 世界其他地區亨汀頓氏舞蹈症治療市場分析、洞察與預測（2021-2034）

第10章 競爭分析

  • 全球市場佔有率分析（2025）
  • 公司簡介
    • Teva Pharmaceutical Industries Ltd.
    • H. Lundbeck A/S
    • Bausch Health Companies Inc.
    • Neurocrine Biosciences, Inc.
    • Prilenia Therapeutics
    • Novartis AG
    • Lupin
    • Hikma Pharmaceuticals PLC
    • Dr. Reddy's Laboratories Ltd.
    • Sun Pharmaceutical Industries, Inc.
Product Code: FBI107140

Growth Factors of Huntington's disease treatment Market

The global Huntington's disease treatment market was valued at USD 1.39 billion in 2025, reflecting the growing demand for symptom-management therapies for this rare and progressive neurodegenerative disorder. The market is projected to reach USD 1.53 billion in 2026 and further expand to USD 4.33 billion by 2034, exhibiting a CAGR of 13.9% during the forecast period. Market growth is supported by increasing disease prevalence in developed regions, rising awareness, and intensified research activities focused on novel therapeutic approaches.

Huntington's disease (HD) is a hereditary condition characterized by the gradual degeneration of nerve cells in the brain, resulting in motor dysfunction, cognitive decline, and psychiatric disturbances. Although no curative therapy exists, approved pharmacological treatments effectively manage chorea and associated symptoms. Currently, tetrabenazine, deutetrabenazine, and valbenazine remain the only globally approved drugs for the treatment of chorea in HD patients.

Market Growth Drivers

A key factor driving market expansion is the increasing prevalence of Huntington's disease, particularly in North America and Europe. According to 2023 estimates, disease prevalence reached 8.87 per 100,000 population in North America and 6.37 per 100,000 in Europe, leading to sustained demand for therapeutic intervention. Rising diagnosis rates in emerging economies such as China and India are further contributing to treatment adoption.

Another major driver is the growing involvement of government bodies and research organizations in funding awareness and clinical development programs. Public-private collaborations and grant funding are accelerating clinical trials aimed at modifying disease progression. Increased diagnostic awareness has resulted in earlier treatment initiation, thereby expanding the addressable patient population.

Market Restraints

Despite favorable growth prospects, the market faces challenges related to adverse effects associated with long-term drug use. Approved therapies such as deutetrabenazine and valbenazine carry warnings related to depression, suicidal ideation, sedation, and cardiac irregularities. These safety concerns may limit patient compliance and prescribing patterns, especially in vulnerable populations.

Additionally, stringent regulatory requirements and lengthy approval timelines for rare-disease drugs pose barriers to rapid commercialization of pipeline candidates, potentially slowing market penetration of novel therapies.

Emerging Market Trends

One of the most prominent trends in the Huntington's disease treatment market is the emergence of advanced genetic and molecular therapies. These include antisense oligonucleotide (ASO) therapies, RNA interference (RNAi), CRISPR-Cas9 gene editing, zinc-finger protein (ZFP) therapies, and TALEN-based approaches. These next-generation modalities aim to target the mutant huntingtin (HTT) gene directly, addressing the root cause of the disease rather than symptom control alone.

Increasing clinical research initiatives and positive early-phase trial data are attracting significant investor and institutional interest, signaling a shift toward disease-modifying strategies.

Segmentation Analysis

By Drug

Based on drug type, tetrabenazine dominated the market, accounting for 64.21% share in 2025. Its dominance is attributed to being the first FDA-approved treatment for HD chorea and the availability of cost-effective generic versions. Deutetrabenazine held a significant share due to improved safety and once-daily formulations, while valbenazine gained traction following recent regulatory approvals for HD-associated chorea. The "others" segment is expected to grow rapidly due to an expanding clinical pipeline and unmet therapeutic needs.

By Distribution Channel

By distribution channel, hospital pharmacies held the largest share and are projected to account for 47.57% of the market in 2026, supported by insurance coverage, specialist supervision, and inpatient treatment requirements. Retail pharmacies continue to play a vital role in prescription refills, while online pharmacies are anticipated to register the fastest growth due to digital healthcare adoption and home delivery convenience.

Regional Insights

North America dominated the global market, valued at USD 1.16 billion in 2025 and USD 1.27 billion in 2026, driven by high disease awareness, strong reimbursement frameworks, and active clinical research ecosystems. The U.S. alone accounted for USD 1.22 billion in 2025.

Europe represented a significant share, supported by increasing commercialization efforts and regulatory submissions for new therapies. Asia Pacific emerged as the second-largest market, projected to reach USD 0.01 billion in 2026, with growth driven by strategic partnerships and improved access to approved drugs. The rest of the world, including Latin America and the Middle East & Africa, showed slower growth due to lower prevalence and limited awareness but presents long-term expansion potential.

Competitive Landscape

The market is led by Teva Pharmaceutical Industries Ltd., driven by strong adoption of its AUSTEDO formulations. Other key players include Neurocrine Biosciences, Inc., H. Lundbeck A/S, Prilenia Therapeutics, and Novartis AG. Continuous product development, regulatory approvals, and global collaborations remain central to competitive strategy as companies seek to address the unmet needs in Huntington's disease treatment.

Report Coverage

The global Huntington's disease treatment market report provides a comprehensive analysis of the industry for the period 2025 to 2034, with 2025 as the base year, 2026 as the estimated year, and 2034 as the forecast year. The report evaluates market size and market value trends, growth outlook, and structural developments influencing the evolution of Huntington's disease therapeutics.

The study covers detailed segmentation by drug type and distribution channel, highlighting adoption patterns of approved therapies such as tetrabenazine, deutetrabenazine, and valbenazine across hospital pharmacies, retail pharmacies, and online platforms. Regional analysis spans North America, Europe, Asia Pacific, and the rest of the world, offering insights into disease prevalence, treatment accessibility, reimbursement environments, and regional research intensity.

In addition, the report examines market drivers, restraints, emerging trends, and pipeline developments, including advances in genetic and molecular therapies such as antisense oligonucleotides, RNA-based treatments, and gene-editing approaches. The competitive landscape section assesses the strategies of leading pharmaceutical and biotechnology companies, focusing on regulatory approvals, clinical trial progress, partnerships, and new formulation launches. The report also incorporates the impact of COVID-19 on diagnosis rates, treatment access, and commercial performance.

Conclusion

The global Huntington's disease treatment market demonstrated steady expansion in 2025, reaching a market value of USD 1.39 billion, supported by increasing disease prevalence, rising diagnostic awareness, and sustained demand for symptom-management therapies. Continued growth to USD 1.53 billion in 2026 and a projected value of USD 4.33 billion by 2034 reflects strong momentum driven by clinical innovation and expanding research activity.

Market growth is primarily supported by the widespread use of approved chorea-management drugs and increasing investment in next-generation disease-modifying therapies. While challenges such as adverse drug reactions and stringent regulatory requirements remain, ongoing clinical trials and government-backed research initiatives are strengthening long-term market prospects.

Regionally, North America maintains market leadership due to high awareness levels, strong reimbursement frameworks, and an active clinical research ecosystem, followed by Europe and Asia Pacific, where expanding access to therapies and strategic partnerships are supporting growth. Overall, the Huntington's disease treatment market is positioned for robust long-term expansion, driven by scientific advancements, rising patient identification, and continued efforts to address significant unmet clinical needs.

Segmentation By Drug

  • Tetrabenazine
  • Deutetrabenazine
  • Valbenazine
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (By Drug, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Drug, Distribution Channel, and Country/Sub-Region)
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific (By Drug, Distribution Channel, and Country/Sub-Region)
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia Pacific
  • Rest of the World (By Drug and Distribution Channel)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Huntington's Diseases, Key Countries/ Regions, 2025
  • 4.2. Key Industry Developments (Mergers, Acquisitions, New Product Launches, etc.)
  • 4.3. Pipeline Analysis, Key Players
  • 4.4. Economic Cost Burden for the Treatment of Huntington's Disease, By Regions
  • 4.5. Regulatory & Reimbursement Scenario, By Key Regions
  • 4.6. Impact of COVID-19 on the Global Huntington's Disease Treatment Market

5. Global Huntington's Disease Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug
    • 5.1.1. Tetrabenazine
    • 5.1.2. Deutetrabenazine
    • 5.1.3. Valbenazine
    • 5.1.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.2.1. Hospital Pharmacies
    • 5.2.2. Drug Stores & Retail Pharmacies
    • 5.2.3. Online Pharmacies
  • 5.3. Market Analysis, Insights and Forecast - By Region
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. Asia Pacific
    • 5.3.4. Rest of the World

6. North America Huntington's Disease Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug
    • 6.1.1. Tetrabenazine
    • 6.1.2. Deutetrabenazine
    • 6.1.3. Valbenazine
    • 6.1.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.2.1. Hospital Pharmacies
    • 6.2.2. Drug Stores & Retail Pharmacies
    • 6.2.3. Online Pharmacies
  • 6.3. Market Analysis, Insights and Forecast - By Country
    • 6.3.1. U.S.
    • 6.3.2. Canada

7. Europe Huntington's Disease Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug
    • 7.1.1. Tetrabenazine
    • 7.1.2. Deutetrabenazine
    • 7.1.3. Valbenazine
    • 7.1.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.2.1. Hospital Pharmacies
    • 7.2.2. Drug Stores & Retail Pharmacies
    • 7.2.3. Online Pharmacies
  • 7.3. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 7.3.1. U.K.
    • 7.3.2. Germany
    • 7.3.3. France
    • 7.3.4. Spain
    • 7.3.5. Italy
    • 7.3.6. Rest of Europe

8. Asia Pacific Huntington's Disease Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug
    • 8.1.1. Tetrabenazine
    • 8.1.2. Deutetrabenazine
    • 8.1.3. Valbenazine
    • 8.1.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.2.1. Hospital Pharmacies
    • 8.2.2. Drug Stores & Retail Pharmacies
    • 8.2.3. Online Pharmacies
  • 8.3. Market Analysis, Insights and Forecast - By Country/Sub-Region
    • 8.3.1. Japan
    • 8.3.2. China
    • 8.3.3. India
    • 8.3.4. Australia
    • 8.3.5. Rest of Asia Pacific

9. Rest of the World Huntington's Disease Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug
    • 9.1.1. Tetrabenazine
    • 9.1.2. Deutetrabenazine
    • 9.1.3. Valbenazine
    • 9.1.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.2.1. Hospital Pharmacies
    • 9.2.2. Drug Stores & Retail Pharmacies
    • 9.2.3. Online Pharmacies

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2025)
  • 10.2. Company Profiles
    • 10.2.1. Teva Pharmaceutical Industries Ltd.
      • 10.2.1.1. Overview
      • 10.2.1.2. Products & services
      • 10.2.1.3. SWOT Analysis
      • 10.2.1.4. Recent Developments
      • 10.2.1.5. Strategies
      • 10.2.1.6. Financials (Based on Availability)
    • 10.2.2. H. Lundbeck A/S
      • 10.2.2.1. Overview
      • 10.2.2.2. Products & services
      • 10.2.2.3. SWOT Analysis
      • 10.2.2.4. Recent Developments
      • 10.2.2.5. Strategies
      • 10.2.2.6. Financials (Based on Availability)
    • 10.2.3. Bausch Health Companies Inc.
      • 10.2.3.1. Overview
      • 10.2.3.2. Products & services
      • 10.2.3.3. SWOT Analysis
      • 10.2.3.4. Recent Developments
      • 10.2.3.5. Strategies
      • 10.2.3.6. Financials (Based on Availability)
    • 10.2.4. Neurocrine Biosciences, Inc.
      • 10.2.4.1. Overview
      • 10.2.4.2. Products & services
      • 10.2.4.3. SWOT Analysis
      • 10.2.4.4. Recent Developments
      • 10.2.4.5. Strategies
      • 10.2.4.6. Financials (Based on Availability)
    • 10.2.5. Prilenia Therapeutics
      • 10.2.5.1. Overview
      • 10.2.5.2. Products & services
      • 10.2.5.3. SWOT Analysis
      • 10.2.5.4. Recent Developments
      • 10.2.5.5. Strategies
      • 10.2.5.6. Financials (Based on Availability)
    • 10.2.6. Novartis AG
      • 10.2.6.1. Overview
      • 10.2.6.2. Products & services
      • 10.2.6.3. SWOT Analysis
      • 10.2.6.4. Recent Developments
      • 10.2.6.5. Strategies
      • 10.2.6.6. Financials (Based on Availability)
    • 10.2.7. Lupin
      • 10.2.7.1. Overview
      • 10.2.7.2. Products & services
      • 10.2.7.3. SWOT Analysis
      • 10.2.7.4. Recent Developments
      • 10.2.7.5. Strategies
      • 10.2.7.6. Financials (Based on Availability)
    • 10.2.8. Hikma Pharmaceuticals PLC
      • 10.2.8.1. Overview
      • 10.2.8.2. Products & services
      • 10.2.8.3. SWOT Analysis
      • 10.2.8.4. Recent Developments
      • 10.2.8.5. Strategies
      • 10.2.8.6. Financials (Based on Availability)
    • 10.2.9. Dr. Reddy's Laboratories Ltd.
      • 10.2.9.1. Overview
      • 10.2.9.2. Products & services
      • 10.2.9.3. SWOT Analysis
      • 10.2.9.4. Recent Developments
      • 10.2.9.5. Strategies
      • 10.2.9.6. Financials (Based on Availability)
    • 10.2.10. Sun Pharmaceutical Industries, Inc.
      • 10.2.10.1. Overview
      • 10.2.10.2. Products & services
      • 10.2.10.3. SWOT Analysis
      • 10.2.10.4. Recent Developments
      • 10.2.10.5. Strategies
      • 10.2.10.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Huntington's Disease Treatment Market Revenue (USD billion) Forecast, By Drug, 2021-2034
  • Table 2: Global Huntington's Disease Treatment Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 3: Global Huntington's Disease Treatment Market Revenue (USD billion) Forecast, By Region, 2021-2034
  • Table 4: North America Huntington's Disease Treatment Market Revenue (USD billion) Forecast, By Drug, 2021-2034
  • Table 5: North America Huntington's Disease Treatment Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 6: North America Huntington's Disease Treatment Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 7: Europe Huntington's Disease Treatment Market Revenue (USD billion) Forecast, By Drug, 2021-2034
  • Table 8: Europe Huntington's Disease Treatment Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 9: Europe Huntington's Disease Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-Region, 2021-2034
  • Table 10: Asia Pacific Huntington's Disease Treatment Market Revenue (USD billion) Forecast, By Drug, 2021-2034
  • Table 11: Asia Pacific Huntington's Disease Treatment Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 12: Asia Pacific Huntington's Disease Treatment Market Revenue (USD billion) Forecast, By Country/ Sub-Region, 2021-2034
  • Table 13: Rest of the World Huntington's Disease Treatment Market Revenue (USD billion) Forecast, By Drug, 2021-2034
  • Table 14: Rest of the World Huntington's Disease Treatment Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034

List of Figures

  • Figure 1: Global Huntington's Disease Treatment Market Value Share (%), By Drug, 2025 & 2034
  • Figure 2: Global Huntington's Disease Treatment Market Value Share (%), By Distribution Channel, 2025 & 2034
  • Figure 3: Global Huntington's Disease Treatment Market Value (USD billion), By Region, 2025 & 2034
  • Figure 4: North America Huntington's Disease Treatment Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 5: North America Huntington's Disease Treatment Market Value Share (%), by Drug, 2025
  • Figure 6: North America Huntington's Disease Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 7: North America Huntington's Disease Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 8: North America Huntington's Disease Treatment Market Value (USD billion), by Country, 2025 & 2034
  • Figure 9: North America Huntington's Disease Treatment Market Value Share (%), by Country, 2025
  • Figure 10: Europe Huntington's Disease Treatment Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 11: Europe Huntington's Disease Treatment Market Value Share (%), by Drug, 2025
  • Figure 12: Europe Huntington's Disease Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 13: Europe Huntington's Disease Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 14: Europe Huntington's Disease Treatment Market Value (USD billion), by Country/ Sub-Region, 2025 & 2034
  • Figure 15: Europe Huntington's Disease Treatment Market Value Share (%), by Country/ Sub-Region, 2025
  • Figure 16: Asia Pacific Huntington's Disease Treatment Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 17: Asia Pacific Huntington's Disease Treatment Market Value Share (%), by Drug, 2025
  • Figure 18: Asia Pacific Huntington's Disease Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 19: Asia Pacific Huntington's Disease Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 20: Asia Pacific Huntington's Disease Treatment Market Value (USD billion), by Country/ Sub-Region, 2025 & 2034
  • Figure 21: Asia Pacific Huntington's Disease Treatment Market Value Share (%), by Country/ Sub-Region, 2025
  • Figure 22: Rest of the World Huntington's Disease Treatment Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 23: Rest of the World Huntington's Disease Treatment Market Value Share (%), by Drug, 2025
  • Figure 24: Rest of the World Huntington's Disease Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 25: Rest of the World Huntington's Disease Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 26: Global Huntington's Disease Treatment Market Share Analysis (%), By Company, 2025